scispace - formally typeset
Open AccessJournal ArticleDOI

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.

TLDR
The latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19 are summarized, and the current treatment and scientific advancements to combat the epidemic novel coronavirus are discussed.
Abstract
An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Nervous system involvement after infection with COVID-19 and other coronaviruses

TL;DR: The research into neurological complications in CoV infections and the possible mechanisms of damage to the nervous system are reviewed.
Journal ArticleDOI

The COVID-19 Cytokine Storm; What We Know So Far.

TL;DR: Targeting cytokines during the management of COVID-19 patients could improve survival rates and reduce mortality.
Journal ArticleDOI

COVID-19 diagnosis and management: a comprehensive review.

TL;DR: An overview of the known clinical features and treatment options for COVID‐19 is provided and quarantine is the only intervention that appears to be effective in decreasing the contagion rate.
Journal ArticleDOI

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.

TL;DR: This study reviews published data on alterations in the expression of different cytokines in patients with COVID-19 who require admission to an intensive care unit to support the design of more effective approaches to the management of CO VID-19.
Journal ArticleDOI

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response.

TL;DR: This review provides a complete review related to structure, origin, and how the body responds to this virus infection and explains the possibility of an immune system over-reaction or cytokine storm.
References
More filters
Journal ArticleDOI

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.

TL;DR: The 2019 novel coronavirus (2019‐nCoV) infection is spreading and its incidence is increasing nationwide, and the first deaths occurred mostly in elderly people, among whom the disease might progress faster.
Journal ArticleDOI

Innate immunity to virus infection.

TL;DR: This review discusses recent advances in the understanding of the mechanisms of viral RNA recognition by these different types of receptors and its relation to acquired immune responses.
Journal ArticleDOI

Effects of chloroquine on viral infections: an old drug against today's diseases

TL;DR: The available information on the effects of chloroquine on viral infections is reviewed, raising the question of whether this old drug may experience a revival in the clinical management of viral diseases such as AIDS and severe acute respiratory syndrome.
Journal ArticleDOI

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

TL;DR: It is demonstrated here that the lysosomotropic-agent-mediated block to SARS-CoV infection is overcome by protease treatment of target-cell-associated virus, and the requirement for cathepsin L proteolysis identifies a previously uncharacterized class of inhibitor for SARS
Related Papers (5)